- ►diabetesjournals.org P Fiorina, A Vergani, S Dada, M Jurewicz, M … - Diabetes, 2008 - Am Diabetes Assoc RESULTS—Anti-CD22/cal monoclonal antibody (mAb) therapy resulted in early and
prolonged B-cell depletion and delayed disease in pre-diabetic mice.
Importantly, when new-onset hyperglycemic mice were treated with the ... Cited by 7 - Related articles - All 4 versions
G Zekavat, SY Rostami, A Badkerhanian, RF … - The Journal of Immunology, 2008 - Am Assoc Immnol B lymphocytes are required for the pathogenesis of autoimmune diabetes in NOD
mice. Previous studies established that a lymphopenic transitional (TR) B cell
compartment reduces the competitive constraint on the entry of newly ... Cited by 6 - Related articles - All 4 versions
- ►jimmunol.org Y Xiu, CP Wong, JD Bouaziz, Y Hamaguchi, Y … - The Journal of Immunology, 2008 - Am Assoc Immnol NOD mice deficient for B lymphocytes from birth fail to develop autoimmune or
type 1 diabetes. To assess whether B cell depletion influences type 1 diabetes
in mice with an intact immune system, NOD female mice representing early ... Cited by 17 - Related articles - All 3 versions
- ►jimmunol.org Y Li, F Chen, M Putt, YK Koo, M Madaio, JC … - The Journal of Immunology, 2008 - Am Assoc Immnol MRL/lpr mice develop a spontaneous systemic lupus erythematosus-like autoimmune
syndrome due to a dysfunctional Fas receptor, with contributions from other less
well-defined genetic loci. The removal of B cells by genetic manipulation ... Cited by 6 - Related articles - All 3 versions
- ►rexnealsmith.com [PDF] P Fiorina, M Jurewicz, A Augello, A Vergani, … - The Journal of Immunology, 2009 - Am Assoc Immnol Human clinical trials in type 1 diabetes (T1D) patients using mesenchymal stem
cells (MSC) are presently underway without prior validation in a mouse model for
the disease. In response to this void, we characterized bone marrow-derived ... Related articles - All 5 versions
SK O'Neill, E Liu, JC Cambier - Current Opinion in Endocrinology, Diabetes and …, 2009 - journals.lww.com Introduction The failure to find a cure for type 1 diabetes has led to the
exploration of efficacious immunotherapies already approved for other diseases.
A recent TrialNet study exploring the use of rituximab in new onset type 1 ... Related articles - All 2 versions
HHM Abdu-Allah, K Watanabe, K Hayashizaki, … - Tetrahedron Letters, 2009 - Elsevier Synthetic ligands tagged with biotin have frequently been utilized to detect,
localize, characterize and recover the target protein. 4 Moreover, in order to
pursue CD22 as a drug target, precise and reproducible binding assays need ... Related articles
PL Kendall, DJ Moore, C Hulbert, KL Hoek, … - The Journal of Immunology, 2009 - Am Assoc Immnol Type 1 diabetes results from T cell-mediated destruction of insulin-producing ß
cells. Although elimination of B lymphocytes has proven successful at preventing
disease, modulation of B cell function as a means to prevent type 1 ... Related articles - All 3 versions
SL Cox, PA Silveira - Expert Review of Clinical Immunology, 2009 - ingentaconnect.com Type 1 diabetes (T1D) is caused by immune infiltration of the pancreatic islets
of Langerhans (referred to as insulitis) followed by specific auto-
immune-mediated destruction of the insulin- secreting b-cells within them ... Related articles - All 3 versions
JK Whitmire, MS Asano, SM Kaech, S Sarkar … - The Journal of Immunology, 2009 - Am Assoc Immnol B cells can influence T cell responses by directly presenting Ag or by secreting
Ab that binds to Ag to form immunogenic complexes. Conflicting evidence suggests
that persisting Ag-Ab complexes propagate long-term T cell memory; yet, ... Cited by 1 - Related articles - All 2 versions
